Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Alzheimer’s Disease | Unmet Need | Agitation in Alzheimer’s Disease | US/EU | 2017

Login to access report north_east
Contact sales account_box

There is increased industry focus on the behavioral symptoms of Alzheimer’s disease (AD), including agitation—and with good reason. Agitation affects the majority of diagnosed AD patients, according to DRG epidemiology, and comprises a constellation of disruptive symptoms for patients and their families. With competing brands from Lundbeck/Otsuka, Avanir/Otsuka, and IntraCellular Therapies (among others) poised to enter the market beginning in 2021, and blockbuster sales at stake, understanding the drivers of clinical decision making in agitation and prescriber perceptions of the risk/benefits of today’s off-label (but generic) options will help identify levers for new product positioning and differentiation in this evolving market.

Questions Answered:

  • What are the treatment drivers and goals for agitation in AD?
  • What attributes are key influencers, which have limited impact, and which are hidden opportunities?
  • How do current therapies perform on key treatment drivers and goals for agitation in AD?
  • What are the prevailing areas of unmet need and opportunity in agitation in AD?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European neurologists for a hypothetical new agitation in AD drug?

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 30 European neurologists fielded in January 2017

Key companies: Lundbeck, Otsuka Pharmaceutical, Avanir Pharmaceuticals

Key drugs: quetiapine, risperidone, olanzapine, haloperidol, citalopram, arpiprazole, lorazepam, brexpiprazole, AVP-786

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Major Depressive Disorder (DSM-V) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Major Depressive Disorder (US)
Major depressive disorder (MDD) is a widely drug-treated condition managed with multiple drug classes, most commonly selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine…
north_east
Report
Atopic Dermatitis / Atopic Eczema – Geographic Focus: China – Atopic Dermatitis – China In-Depth (China)
China’s atopic dermatitis (AD) market remains grounded in established topical and systemic therapies, although limitations in longterm disease control leave a sizable unmet need among…
north_east
Report
Dry and Wet Age-Related Macular Degeneration – Access & Reimbursement – Access & Reimbursement – Age-Related Macular Degeneration (US)
The U.S. wet AMD market is led by intravitreal therapies such as Eylea, Eylea HD, and Vabysmo, alongside the continued off-label use of compounded Avastin, driven by cost considerations. In…
north_east
Report
Psoriatic Arthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Psoriatic Arthritis (US)
Treatment of psoriatic arthritis (PsA) typically begins with conventional disease-modifying antirheumatic drugs (DMARDs), such as methotrexate, and progresses to more potent biologics and/or…
north_east
Report
Peripheral Arterial Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Peripheral Artery Disease (US)
Peripheral artery disease (PAD) is a subtype of atherosclerotic cardiovascular disease affecting the arteries of the lower extremities and is associated with reduced walking capacity, claudication…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east